113 related articles for article (PubMed ID: 10952250)
1. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta.
Shiratori Y; Perelson AS; Weinberger L; Imazeki F; Yokosuka O; Nakata R; Ihori M; Hirota K; Ono N; Kuroda H; Motojima T; Nishigaki M; Omata M
J Hepatol; 2000 Aug; 33(2):313-22. PubMed ID: 10952250
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.
Kakizaki S; Takagi H; Yamada T; Ichikawa T; Abe T; Sohara N; Kosone T; Kaneko M; Takezawa J; Takayama H; Nagamine T; Mori M
J Viral Hepat; 1999 Jul; 6(4):315-9. PubMed ID: 10607246
[TBL] [Abstract][Full Text] [Related]
3. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
4. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C.
Kaito M; Yasui-Kawamura N; Iwasa M; Kobayashi Y; Nakagawa N; Fujita N; Ikoma J; Gabazza EC; Watanabe S; Adachi Y
Hepatogastroenterology; 2003; 50(51):775-8. PubMed ID: 12828083
[TBL] [Abstract][Full Text] [Related]
5. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.
Furusyo N; Hayashi J; Ohmiya M; Sawayama Y; Kawakami Y; Ariyama I; Kinukawa N; Kashiwagi S
Dig Dis Sci; 1999 Mar; 44(3):608-17. PubMed ID: 10080158
[TBL] [Abstract][Full Text] [Related]
6. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice-daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin.
Nakajima H; Shimomura H; Iwasaki Y; Ikeda F; Umeoka F; Chengyu P; Taniguchi H; Ohnishi Y; Takagi SJ; Fujioka S; Shiratori Y
Acta Med Okayama; 2003 Oct; 57(5):217-25. PubMed ID: 14679399
[TBL] [Abstract][Full Text] [Related]
7. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen.
Suzuki F; Chayama K; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2001 Apr; 36(4):242-7. PubMed ID: 11324727
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
[TBL] [Abstract][Full Text] [Related]
10. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
[TBL] [Abstract][Full Text] [Related]
11. Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C.
Mochizuki K; Kagawa T; Takashimizu S; Kawazoe K; Kojima S; Nagata N; Nakano A; Nishizaki Y; Shiraishi K; Itakura M; Watanabe N; Mine T; Matsuzaki S
World J Gastroenterol; 2004 Mar; 10(5):733-6. PubMed ID: 14991949
[TBL] [Abstract][Full Text] [Related]
12. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
[TBL] [Abstract][Full Text] [Related]
13. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
14. Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study.
Izumi N; Kumada H; Hashimoto N; Harada H; Imawari M; Zeniya M; Toda G
Dig Dis Sci; 2001 Mar; 46(3):516-23. PubMed ID: 11318525
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.
Arase Y; Suzuki F; Sezaki H; Kawamura Y; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Yatsuji H; Kobayashi M; Saitoh S; Ikeda K; Kumada H
Intern Med; 2008; 47(12):1085-90. PubMed ID: 18552464
[TBL] [Abstract][Full Text] [Related]
16. Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course.
Arase Y; Ikeda K; Chayama K; Murashima N; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Kumada H
J Gastroenterol; 2000; 35(8):607-12. PubMed ID: 10955599
[TBL] [Abstract][Full Text] [Related]
17. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
[TBL] [Abstract][Full Text] [Related]
18. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
19. Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta.
Ikeda F; Shimomura H; Miyake M; Fujioka SI; Itoh M; Takahashi A; Iwasaki Y; Sakaguchi K; Yamamoto K; Higashi T; Tsuji T
J Interferon Cytokine Res; 2000 Sep; 20(9):831-6. PubMed ID: 11032403
[TBL] [Abstract][Full Text] [Related]
20. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C.
Nakamura H; Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S
Hepatogastroenterology; 2003; 50(49):222-6. PubMed ID: 12630027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
